UBS Maintains Buy on Abbott Laboratories (ABT) March 13, 2026

UBS maintained a Buy rating on Abbott Laboratories (ABT) on March 13, 2026, marking a continued vote of confidence in the company’s medical-device and diagnostics growth. The ABT analyst rating note emphasized durable demand in diagnostic testing and device replacement cycles. UBS did not publish a new price target in the note. Read UBS note on StreetInsider

ABT analyst rating: UBS maintains Buy on March 13, 2026

UBS reiterated Buy for Abbott Laboratories on March 13, 2026. The note was logged at 09:37 AM and showed a minor market reaction of 0.09% ($0.1) since the comment. source

Analyst rationale behind the maintained Buy

UBS cited sustained growth in Abbott’s diagnostics division and durable demand in core medical devices as the core reasons for the maintained Buy rating. The firm framed its view around product cycles and recurring revenue from installed device bases.

Price targets and what UBS did not change

UBS did not issue a fresh ABT price target in the March 13, 2026 note, leaving prior estimates intact. Investors should treat the maintained Buy as confirmation of conviction, not a fresh valuation reset.

Market impact and investor implications

The maintained Buy typically signals steady analyst conviction and can support investor confidence in medium-term upside. At the time of the note the stock moved about 0.09% ($0.1) and Abbott had a market cap of $187,704,505,454.

Historical context of Abbott analyst coverage

Abbott has generally attracted positive coverage from major firms on device and diagnostics strength. UBS’s March 13, 2026 reiteration continues a pattern of periodic Buy confirmations tied to product durability and recurring revenue streams.

Key catalysts to watch after the maintained rating

Investors should watch quarterly sales for diagnostics and device replacement rates, regulatory updates, and competitor moves. These catalysts will determine whether analysts add fresh price targets or adjust ratings.

Final Thoughts

UBS’s decision to maintain a Buy on Abbott Laboratories on March 13, 2026 leaves the ABT analyst rating unchanged and signals continued confidence in diagnostics and medical-device cash flows. The firm did not supply a new price target, so investors should treat the note as a reinforcement of existing views rather than a valuation reset. Short-term market reaction was muted, with a 0.09% ($0.1) intraday move at the time of the note. Abbott’s market cap stood at $187,704,505,454, a reminder of its scale in the health-care sector. Meyka AI rates ABT with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and do not constitute financial advice. For ongoing coverage see our ABT page at https://meyka.ai/stocks/ABT and the UBS note on StreetInsider for primary detail source and broader analyst headlines at Investing.com.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.